According to the official website of the National Medical Products Administration, recently, the National Medical Products Administration approved the listing of Shenyu Ningshen Tablet, a Class 1.1 innovative traditional Chinese medicine declared by Guangdong Siji Pharmaceutical Co., Ltd. It is reported that the drug has undergone a randomized, double-blind, placebo-controlled multicenter clinical trial. The clinical trial results show that the main efficacy indicators (HAMD-17 score reduction rate ≥ 50% is effective) are more effective compared between groups, and the efficacy of the experimental group is better than that of the placebo group. This medicine benefits qi and nourishes yin, calms the mind and relieves depression. Suitable for mild to moderate depression, which belongs to the syndrome of qi and yin deficiency in traditional Chinese medicine. The launch of this drug provides another treatment option for patients with depression. (Outlook New Era Network)